Novartis' Zykadia gets a front-line boost in lung cancer race against Roche

NovartisHQClose
Novartis' Zykadia and Roche's Alecensa are both gunning for front-line nods in ALK+ NSCLC.

Novartis isn’t letting its crosstown rival get all the regulatory attention when it comes to ALK+ metastatic non-small cell lung cancer.

On Thursday, it moved toward evening the score with nemesis Roche, winning an FDA priority review for cancer-fighter Zykadia as a first-line treatment for patients with the disease. It also picked up the agency’s breakthrough designation for first-line treatment of ALK+ NSCLC patients with brain metastases.

It’s a step in the right direction for Zykadia, which is currently approved for patients who have already failed on Pfizer’s Xalkori. Last September, the Novartis med showed it could top standard chemo at improving progression-free survival in the front-line setting, hitting secondary endpoints in objective response rate and duration of response, too.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

Still, though, it’s trailing behind Roche competitor Alecensa, both in the regulatory race and in the sales department. Alecensa picked up a first-line breakthrough tag from the FDA last October, and through the first half of last year, it generated $74 million compared with Zykadia’s $48 million.

That’s partly because Zykadia hasn’t seen much expansion lately. In 2016’s Q3, it brought in $21 million in sales—the same figure it reached in that period the year prior.

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.